Funding for the FDA and the NIH are a top political concern for the biotech sector this year because of their impact on new drug approval and development, BIO President Jim Greenwood said in an interview with the San Diego Union-Tribune. Greenwood also discussed the need for 14 years of market exclusivity in legislation to create a regulatory pathway for approving follow-on biologics, as well as the importance of allowing a doctor to determine drug interchangeability.

Related Summaries